Spotlight on Genetic Kidney Diseases: A Call for Drug Delivery and Nanomedicine Solutions
Nanoparticles as drug delivery carriers have benefited diseases, including cancer, since the 1990s, and more recently, their promise to quickly and efficiently be mobilized to fight against global diseases such as in the COVID-19 pandemic have been proven. Despite these success stories, there are li...
Gespeichert in:
| Veröffentlicht in: | ACS nano 2023-04, Vol.17 (7), p.6165-6177 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6177 |
|---|---|
| container_issue | 7 |
| container_start_page | 6165 |
| container_title | ACS nano |
| container_volume | 17 |
| creator | Trac, Noah Ashraf, Anisa Giblin, Joshua Prakash, Supriya Mitragotri, Samir Chung, Eun Ji |
| description | Nanoparticles as drug delivery carriers have benefited diseases, including cancer, since the 1990s, and more recently, their promise to quickly and efficiently be mobilized to fight against global diseases such as in the COVID-19 pandemic have been proven. Despite these success stories, there are limited nanomedicine efforts for chronic kidney diseases (CKDs), which affect 844 million people worldwide and can be linked to a variety of genetic kidney diseases. In this Perspective, we provide a brief overview of the clinical status of genetic kidney diseases, background on kidney physiology and a summary of nanoparticle design that enable kidney access and targeting, and emerging technological strategies that can be applied for genetic kidney diseases, including rare and congenital kidney diseases. Finally, we conclude by discussing gaps in knowledge remaining in both genetic kidney diseases and kidney nanomedicine and collective efforts that are needed to bring together stakeholders from diverse expertise and industries to enable the development of the most relevant drug delivery strategies that can make an impact in the clinic. |
| doi_str_mv | 10.1021/acsnano.2c12140 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10145694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2792502308</sourcerecordid><originalsourceid>FETCH-LOGICAL-a430t-a273579dd3e3947be677521a5e6ff32f4d0fae099b01936773f5b1d2066b9f03</originalsourceid><addsrcrecordid>eNp1kcFPHCEUxknTplrt2Zvh2KRZfcAMDF6M2W1tU1MPetATYWYeK4aFLcyY7H_fMbvdtIeeHsn7fR8ffIScMDhjwNm57Uq0MZ3xjnFWwRtyyLSQM2jkw9v9uWYH5EMpzwC1apR8Tw6E1E3DQR2Sx7t1GoJfPg00RXqNEQff0R--j7ihC1_QFiwX9IrObQjUpUwXeVzSBQb_gnlDbezpzynBCnvf-Yj0LoVx8CmWY_LO2VDw424ekfuvX-7n32Y3t9ff51c3M1sJGGaWK1Er3fcCha5Ui1KpmjNbo3ROcFf14CyC1i28Pkcp4eqW9RykbLUDcUQut7brsZ1CdBiHbINZZ7-yeWOS9ebfTfRPZpleDANW1VJXk8OnnUNOv0Ysg1n50mEINmIai-FK8xq4gGZCz7dol1MpGd3-HgbmtRCzK8TsCpkUp3_H2_N_GpiAz1tgUprnNOY4fdZ_7X4D6K2XUA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2792502308</pqid></control><display><type>article</type><title>Spotlight on Genetic Kidney Diseases: A Call for Drug Delivery and Nanomedicine Solutions</title><source>MEDLINE</source><source>American Chemical Society Web Editions</source><creator>Trac, Noah ; Ashraf, Anisa ; Giblin, Joshua ; Prakash, Supriya ; Mitragotri, Samir ; Chung, Eun Ji</creator><creatorcontrib>Trac, Noah ; Ashraf, Anisa ; Giblin, Joshua ; Prakash, Supriya ; Mitragotri, Samir ; Chung, Eun Ji</creatorcontrib><description>Nanoparticles as drug delivery carriers have benefited diseases, including cancer, since the 1990s, and more recently, their promise to quickly and efficiently be mobilized to fight against global diseases such as in the COVID-19 pandemic have been proven. Despite these success stories, there are limited nanomedicine efforts for chronic kidney diseases (CKDs), which affect 844 million people worldwide and can be linked to a variety of genetic kidney diseases. In this Perspective, we provide a brief overview of the clinical status of genetic kidney diseases, background on kidney physiology and a summary of nanoparticle design that enable kidney access and targeting, and emerging technological strategies that can be applied for genetic kidney diseases, including rare and congenital kidney diseases. Finally, we conclude by discussing gaps in knowledge remaining in both genetic kidney diseases and kidney nanomedicine and collective efforts that are needed to bring together stakeholders from diverse expertise and industries to enable the development of the most relevant drug delivery strategies that can make an impact in the clinic.</description><identifier>ISSN: 1936-0851</identifier><identifier>EISSN: 1936-086X</identifier><identifier>DOI: 10.1021/acsnano.2c12140</identifier><identifier>PMID: 36988207</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>COVID-19 ; Drug Carriers - therapeutic use ; Drug Delivery Systems ; Humans ; Kidney ; Kidney Diseases - drug therapy ; Kidney Diseases - genetics ; Nanomedicine ; Nanoparticles ; Pandemics</subject><ispartof>ACS nano, 2023-04, Vol.17 (7), p.6165-6177</ispartof><rights>2023 American Chemical Society</rights><rights>2023 American Chemical Society 2023 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a430t-a273579dd3e3947be677521a5e6ff32f4d0fae099b01936773f5b1d2066b9f03</citedby><cites>FETCH-LOGICAL-a430t-a273579dd3e3947be677521a5e6ff32f4d0fae099b01936773f5b1d2066b9f03</cites><orcidid>0000-0002-7726-5555 ; 0000-0002-2459-8305</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsnano.2c12140$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsnano.2c12140$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,314,780,784,885,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36988207$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Trac, Noah</creatorcontrib><creatorcontrib>Ashraf, Anisa</creatorcontrib><creatorcontrib>Giblin, Joshua</creatorcontrib><creatorcontrib>Prakash, Supriya</creatorcontrib><creatorcontrib>Mitragotri, Samir</creatorcontrib><creatorcontrib>Chung, Eun Ji</creatorcontrib><title>Spotlight on Genetic Kidney Diseases: A Call for Drug Delivery and Nanomedicine Solutions</title><title>ACS nano</title><addtitle>ACS Nano</addtitle><description>Nanoparticles as drug delivery carriers have benefited diseases, including cancer, since the 1990s, and more recently, their promise to quickly and efficiently be mobilized to fight against global diseases such as in the COVID-19 pandemic have been proven. Despite these success stories, there are limited nanomedicine efforts for chronic kidney diseases (CKDs), which affect 844 million people worldwide and can be linked to a variety of genetic kidney diseases. In this Perspective, we provide a brief overview of the clinical status of genetic kidney diseases, background on kidney physiology and a summary of nanoparticle design that enable kidney access and targeting, and emerging technological strategies that can be applied for genetic kidney diseases, including rare and congenital kidney diseases. Finally, we conclude by discussing gaps in knowledge remaining in both genetic kidney diseases and kidney nanomedicine and collective efforts that are needed to bring together stakeholders from diverse expertise and industries to enable the development of the most relevant drug delivery strategies that can make an impact in the clinic.</description><subject>COVID-19</subject><subject>Drug Carriers - therapeutic use</subject><subject>Drug Delivery Systems</subject><subject>Humans</subject><subject>Kidney</subject><subject>Kidney Diseases - drug therapy</subject><subject>Kidney Diseases - genetics</subject><subject>Nanomedicine</subject><subject>Nanoparticles</subject><subject>Pandemics</subject><issn>1936-0851</issn><issn>1936-086X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFPHCEUxknTplrt2Zvh2KRZfcAMDF6M2W1tU1MPetATYWYeK4aFLcyY7H_fMbvdtIeeHsn7fR8ffIScMDhjwNm57Uq0MZ3xjnFWwRtyyLSQM2jkw9v9uWYH5EMpzwC1apR8Tw6E1E3DQR2Sx7t1GoJfPg00RXqNEQff0R--j7ihC1_QFiwX9IrObQjUpUwXeVzSBQb_gnlDbezpzynBCnvf-Yj0LoVx8CmWY_LO2VDw424ekfuvX-7n32Y3t9ff51c3M1sJGGaWK1Er3fcCha5Ui1KpmjNbo3ROcFf14CyC1i28Pkcp4eqW9RykbLUDcUQut7brsZ1CdBiHbINZZ7-yeWOS9ebfTfRPZpleDANW1VJXk8OnnUNOv0Ysg1n50mEINmIai-FK8xq4gGZCz7dol1MpGd3-HgbmtRCzK8TsCpkUp3_H2_N_GpiAz1tgUprnNOY4fdZ_7X4D6K2XUA</recordid><startdate>20230411</startdate><enddate>20230411</enddate><creator>Trac, Noah</creator><creator>Ashraf, Anisa</creator><creator>Giblin, Joshua</creator><creator>Prakash, Supriya</creator><creator>Mitragotri, Samir</creator><creator>Chung, Eun Ji</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7726-5555</orcidid><orcidid>https://orcid.org/0000-0002-2459-8305</orcidid></search><sort><creationdate>20230411</creationdate><title>Spotlight on Genetic Kidney Diseases: A Call for Drug Delivery and Nanomedicine Solutions</title><author>Trac, Noah ; Ashraf, Anisa ; Giblin, Joshua ; Prakash, Supriya ; Mitragotri, Samir ; Chung, Eun Ji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a430t-a273579dd3e3947be677521a5e6ff32f4d0fae099b01936773f5b1d2066b9f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>COVID-19</topic><topic>Drug Carriers - therapeutic use</topic><topic>Drug Delivery Systems</topic><topic>Humans</topic><topic>Kidney</topic><topic>Kidney Diseases - drug therapy</topic><topic>Kidney Diseases - genetics</topic><topic>Nanomedicine</topic><topic>Nanoparticles</topic><topic>Pandemics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Trac, Noah</creatorcontrib><creatorcontrib>Ashraf, Anisa</creatorcontrib><creatorcontrib>Giblin, Joshua</creatorcontrib><creatorcontrib>Prakash, Supriya</creatorcontrib><creatorcontrib>Mitragotri, Samir</creatorcontrib><creatorcontrib>Chung, Eun Ji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS nano</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trac, Noah</au><au>Ashraf, Anisa</au><au>Giblin, Joshua</au><au>Prakash, Supriya</au><au>Mitragotri, Samir</au><au>Chung, Eun Ji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spotlight on Genetic Kidney Diseases: A Call for Drug Delivery and Nanomedicine Solutions</atitle><jtitle>ACS nano</jtitle><addtitle>ACS Nano</addtitle><date>2023-04-11</date><risdate>2023</risdate><volume>17</volume><issue>7</issue><spage>6165</spage><epage>6177</epage><pages>6165-6177</pages><issn>1936-0851</issn><eissn>1936-086X</eissn><abstract>Nanoparticles as drug delivery carriers have benefited diseases, including cancer, since the 1990s, and more recently, their promise to quickly and efficiently be mobilized to fight against global diseases such as in the COVID-19 pandemic have been proven. Despite these success stories, there are limited nanomedicine efforts for chronic kidney diseases (CKDs), which affect 844 million people worldwide and can be linked to a variety of genetic kidney diseases. In this Perspective, we provide a brief overview of the clinical status of genetic kidney diseases, background on kidney physiology and a summary of nanoparticle design that enable kidney access and targeting, and emerging technological strategies that can be applied for genetic kidney diseases, including rare and congenital kidney diseases. Finally, we conclude by discussing gaps in knowledge remaining in both genetic kidney diseases and kidney nanomedicine and collective efforts that are needed to bring together stakeholders from diverse expertise and industries to enable the development of the most relevant drug delivery strategies that can make an impact in the clinic.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>36988207</pmid><doi>10.1021/acsnano.2c12140</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-7726-5555</orcidid><orcidid>https://orcid.org/0000-0002-2459-8305</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1936-0851 |
| ispartof | ACS nano, 2023-04, Vol.17 (7), p.6165-6177 |
| issn | 1936-0851 1936-086X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10145694 |
| source | MEDLINE; American Chemical Society Web Editions |
| subjects | COVID-19 Drug Carriers - therapeutic use Drug Delivery Systems Humans Kidney Kidney Diseases - drug therapy Kidney Diseases - genetics Nanomedicine Nanoparticles Pandemics |
| title | Spotlight on Genetic Kidney Diseases: A Call for Drug Delivery and Nanomedicine Solutions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T18%3A36%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spotlight%20on%20Genetic%20Kidney%20Diseases:%20A%20Call%20for%20Drug%20Delivery%20and%20Nanomedicine%20Solutions&rft.jtitle=ACS%20nano&rft.au=Trac,%20Noah&rft.date=2023-04-11&rft.volume=17&rft.issue=7&rft.spage=6165&rft.epage=6177&rft.pages=6165-6177&rft.issn=1936-0851&rft.eissn=1936-086X&rft_id=info:doi/10.1021/acsnano.2c12140&rft_dat=%3Cproquest_pubme%3E2792502308%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2792502308&rft_id=info:pmid/36988207&rfr_iscdi=true |